Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.

OBJECTIVES: Our objective was to evaluate the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a real-world setting in Belgium. METHODS: This was a retrospective, multicentre cohort study involving adult treatment-naïve (TN) and treatment-experienced (TE) people living with HIV receiving BIC/FTC/TAF between 1 January 2019 and 30 September 2020. The primary outcome was rate of virological suppression (plasma HIV-1 viral load <50 copies/mL; on-treatment analysis) at weeks 24 and 48. The main secondary outcomes included loss of virolog... Mehr ...

Volltext
Verfasser: Nasreddine, Rakan
Florence, Eric
Yombi, Jean Cyr
Henrard, Sophie
Darcis, Gilles
Van Praet, Jens
Vandekerckhove, Linos
Allard, Sabine D
Demeester, Rémy
Messiaen, Peter
Ausselet, Nathalie
Delforge, Marc
De Wit, Stéphane
Belgian Research on AIDS and HIV Consortium (BREACH)
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Verlag/Hrsg.: Wiley
Schlagwörter: Adult / Humans / Female / Middle Aged / HIV Infections / Emtricitabine / Belgium / Retrospective Studies / Cohort Studies / Adenine / Treatment Outcome / Heterocyclic Compounds / 3-Ring / Drug Combinations / 4 or More Rings / Anti-HIV Agents / HIV / bictegravir/emtricitabine/tenofovir alafenamide / efficacy / real-world data / tolerability
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26588451
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/281457